A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC)

被引：0
|
作者：
Angevin, E.
Gruenwald, V.
Ravaud, A.
Castellano, D. E.
Lin, C. C.
Gschwend, J. E.
Harzstark, A. L.
Chang, J.
Wang, Y.
Shi, M. M.
Escudier, B. J.
机构：
[1] Inst Gustave Roussy, Villejuif, France
[2] Hannover Med Sch, D-30623 Hannover, Germany
[3] Hop St Andre CHU, Bordeaux, France
[4] Hosp Univ 12 Octubre, Madrid, Spain
[5] Natl Taiwan Univ Hosp, Taipei, Taiwan
[6] Tech Univ Munich, D-80290 Munich, Germany
[7] Univ Calif San Francisco, San Francisco, CA 94143 USA
[8] Novartis Pharmaceut, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4551
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Phase II study of lenalidomide in patients (pts) with metastatic renal cell cancer (MRCC).
    Marsh, L.
    Khan, M.
    Needle, M.
    Amato, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 224S - 224S
  • [32] A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
    Vincent A. de Weger
    Sanjay Goel
    Roger von Moos
    Jan H. M. Schellens
    Nicholas Mach
    Eugene Tan
    Suraj Anand
    Jeffrey W. Scott
    Ulrik Lassen
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 73 - 80
  • [33] Phase II study of second line pazopanib in patients with metastatic renal cell carcinoma (mRCC) previously treated with a tyrosine kinase inhibitor (TKI).
    Esteban, Emilio
    del Muro, Xavier Garcia
    Sepulveda, Juan Manuel
    Maroto, Pablo
    Diaz, Enrique Gallardo
    del Alba, Aranzazu Gonzalez
    Etxaniz, Olatz
    Guix, Marta
    Gonzalez-Larriba, Jose-Luis
    Arija, Jose Angel Arranz
    Bellmunt, Joaquim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC)
    Kim, Hye Ryun
    Kang, Han Na
    Kim, Sung Moo
    Kim, Hwan
    Pyo, Kyoung-Ho
    Ahn, Myung-Ju
    Kim, Tae Min
    Cho, Byoung Chul
    CANCER RESEARCH, 2016, 76
  • [35] ERLOTINIB (E) AND DOVITINIB (TKI258) (D) IN PATIENTS (PTS) WITH METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): A SIGNIFICANT PHARMACOKINETIC (PK) INTERACTION
    Das, Millie
    Padda, Sukhmani K.
    Zhou, Lisa
    Frymoyer, Adam
    Neal, Joel W.
    Wakelee, Heather A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1185 - S1186
  • [36] A phase II multicenter study of stereotactic radiotherapy (SRT) for oligoprogression in metastatic renal cell cancer (mRCC) patients receiving tyrosine kinase inhibitor (TKI) therapy.
    Cheung, Patrick
    Patel, Samir
    North, Scott A.
    Sahgal, Arjun
    Chu, William
    Soliman, Hany
    Ahmad, Belal
    Winquist, Eric
    Patenaude, Francois
    Niazi, Tamim
    Heng, Daniel Yick Chin
    Lim, Gerald
    Dubey, Arbind
    Czaykowski, Piotr
    Wong, Rebecca
    Swaminath, Anand
    Morgan, Scott Carlyle
    White, Justin
    Keshavarzi, Sareh
    Bjarnason, Georg A.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Dovitinib (TKI258) or placebo in combination with fulvestrant in postmenopausal, endocrine-resistant HER2/HR+ breast cancer: a phase II study
    Andre, F.
    Greil, R.
    Denduluri, N.
    Barrios, C.
    Campone, M.
    Cortes, J.
    Neven, P.
    Reddick, C.
    Squires, M.
    Zhang, Y.
    Yovine, A.
    Blackwell, K.
    CANCER RESEARCH, 2012, 72
  • [38] A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors
    de Weger, Vincent A.
    Goel, Sanjay
    von Moos, Roger
    Schellens, Jan H. M.
    Mach, Nicholas
    Tan, Eugene
    Anand, Suraj
    Scott, Jeffrey W.
    Lassen, Ulrik
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (01) : 73 - 80
  • [39] Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study
    Konecny, Gottfried E.
    Finkler, Neil
    Garcia, Agustin A.
    Lorusso, Domenica
    Lee, Paula S.
    Rocconi, Rodney P.
    Fong, Peter C.
    Squires, Matt
    Mishra, Kaushal
    Upalawanna, Allison
    Wang, Yongyu
    Kristeleit, Rebecca
    LANCET ONCOLOGY, 2015, 16 (06): : 686 - 694
  • [40] A phase II study of patients with advanced or metastatic renal cell carcinoma (mRCC) receiving pazopanib after previous checkpoint inhibitor treatment
    Powles, T. B.
    Oudard, S.
    Grunwald, V.
    Calvo, E.
    Michaelson, M. D.
    Burotto, M.
    Melichar, B.
    Tyagi, R.
    Hilmi, F.
    Gaur, A.
    Hirschberg, Y.
    Heng, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S564 - S564
12345